Is Revolution Medicines, Inc. (RVMD) a Buy, Sell, or Hold?
Revolution Medicines, Inc.
NASDAQ:RVMD
$184.97 USD
$1.02 (0.55%)
- Volume
- 3.12M
- Average Volume
- 3.26M
- Market Capitalization
- $39.32B
- P/E Ratio
- -26.02
- Dividend Yield
- 0.00%
- Price Target
- $195.00
- Year High
- $193.83
- Year Low
- $34.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.80
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Mark A. Goldsmith |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | RVMD |
| CUSIP | 76155X100 |
| CIK | 0001628171 |
| Web | https://www.revmed.com |
| Phone | 650 481 6801 |
| Currency | USD |
| Employees | 883 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.29 |
| Payout Ratio | 0.00 |
| Current Ratio | 6.80 |
| Quick Ratio | 6.80 |
| Cash Ratio | 1.52 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -5.41 |
| Price / Cash Flow | -36.69 |
| Price / Book | 24.43 |
Price Target and Rating
| Average Stock Price Forecast | $195.00 |
| High Stock Price Forecast | $235.00 |
| Low Stock Price Forecast | $144.00 |
| Forecast Upside/Downside | -5.14% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 23 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-5.95 |
| Trailing P/E Ratio | -26.02 |
| PEG Ratio | 0.53 |
| P/E Growth | 0.53 |
| Net Income | $-1.13B |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -83.22% |
| Return on Assets | -60.86% |
Financials Score
| AltmanZ Score | 28.17 |
| Piotroski Score | 1.00 |
| Working Capital | 1.68B |
| Total Assets | 2.25B |
| Ebit | -1.34B |
| Market Cap | 39.32B |
| Total Liabilities | 753.82M |
Poll Results
About Revolution Medicines, Inc. (NASDAQ:RVMD) Stock
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG ... 12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
5 Stock Setups Where Wall Street Sees the Most Upside Right Now
2026-07-12 22:44:47
The S&P 500 is up 10.3% YTD, and Wall Street is convinced the markets have more room to run, particularly for this group of stocks we have uncovered. JPMorgan just tagged CECO Environmental (NASDAQ: CECO) with a $130 price target, implying roughly 65% upside from where the stock closed Friday. Bigger and more interesting calls landed on... 5 Stock Setups Where Wall Street Sees the Most Upside Right Now
Better Growth Buy: Axsome vs Revolution Medicines
2026-07-09 03:55:00
Axsome has a solid late-stage pipeline and growing commercialized drugs. Revolution aims to revolutionize cancer treatment, and a recent phase 3 trial shows it may be on the right path.
2026-07-07 09:23:00
REDWOOD CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has started a phased review of data on daraxonrasib, the company's investigational RAS(ON) multi-selective inhibitor. A phased review aims to accelerate the assessment of a medicine by evaluating the data in phases as they become available, ahead of the submission of a full marketing authorization application. Daraxonrasib was designated by the EMA as an orphan medicinal product for the treatment of pancreatic cancer and has been recognized as a high priority under EMA's Cancer Medicines Pathfinder project based on its potential to address a high unmet medical need.
EMA fast-tracks review of Revolutions' experimental pancreatic cancer pill
2026-07-07 09:09:39
The European Medicines Agency said on Tuesday it has begun a rolling review of Revolution Medicines' experimental treatment for patients with metastatic pancreatic cancer.
2026-07-06 18:10:00
Each of these biotech players has reached an important turning point. Recent drug approvals could supercharge the performance of one in particular.
Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?
2026-07-05 19:15:00
Revolution Medicines has taken a new approach to the treatment of certain cancers. The company's lead product is approaching the regulatory review stage.
2026-07-02 08:00:00
REDWOOD CITY, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced results from two Phase 1/2 clinical trials evaluating zoldonrasib, its oral RAS(ON) G12D-selective covalent inhibitor, in combination regimens for patients with RAS G12D metastatic pancreatic ductal adenocarcinoma (PDAC).
2026-07-01 16:37:00
Revolution Medicines' cancer drugs in development could establish new standards of care in some niches. The biotech company may launch its leading candidate within the next year.
Frequently Asked Questions
-
What is the current Revolution Medicines, Inc. (RVMD) stock price?
-
Revolution Medicines, Inc.(NASDAQ:RVMD) stock price is $184.97 in the last trading session. During the trading session, RVMD stock reached the peak price of $193.825 while $34 was the lowest point it dropped to. The percentage change in RVMD stock occurred in the recent session was 0.55% while the dollar amount for the price change in RVMD stock was $1.02.
-
RVMD's industry and sector of operation?
-
The NASDAQ listed RVMD is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of RVMD?
-
Stephen Kelsey Path. FRCP | Senior Advisor
Jack Anders | Chief Financial Officer
Erin Graves | Senior Director of Corporate Communications & Investor Relations
Martin D. Burke | Co-Founder & Chairman of Scientific Advisory Board
Mark A. Goldsmith | Chief Executive Officer, President & Chairman -
How many employees does RVMD have?
-
Number of RVMD employees currently stands at 883. RVMD operates from 700 Saginaw Drive, Redwood City, CA 94063, US.
-
Link for RVMD official website?
-
Official Website of RVMD is: https://www.revmed.com
-
How do I contact RVMD?
-
RVMD could be contacted at phone #650 481 6801 and can also be accessed through its website. RVMD operates from 700 Saginaw Drive, Redwood City, CA 94063, US.
-
How many shares of RVMD are traded daily?
-
The average number of RVMD shares traded daily for last 3 months was 3.26M.
-
What is the market cap of RVMD currently?
-
The market value of RVMD currently stands at $39.32B with its latest stock price at $184.97